Peter Heerma Sells 2,174 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Peter Heerma sold 2,174 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $46.65, for a total transaction of $101,417.10. Following the completion of the sale, the insider directly owned 140,684 shares of the company’s stock, valued at $6,562,908.60. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peter Heerma also recently made the following trade(s):

• On Tuesday, April 14th, Peter Heerma sold 7,215 shares of Travere Therapeutics stock. The stock was sold at an average price of $41.93, for a total transaction of $302,524.95.

Travere Therapeutics Price Performance

NASDAQ TVTX opened at $42.66 on Friday. The company has a 50 day simple moving average of $32.83 and a 200-day simple moving average of $32.94. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of -185.47 and a beta of 1.13. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $48.61.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm’s revenue was up 55.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.47) earnings per share. Equities research analysts predict that Travere Therapeutics, Inc. will post -0.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TVTX. JPMorgan Chase & Co. reduced their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. TD Cowen increased their price objective on Travere Therapeutics from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity Group increased their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Weiss Ratings downgraded Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Finally, Wall Street Zen downgraded Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.83.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analyst upgrades and price‑target increases — Wells Fargo moved to “overweight” and raised its target to $50, joining several firms that have lifted targets and reiterated buy ratings, which supports buying interest. Read More.
• Positive Sentiment: Q1 results showed an EPS beat and ~55.6% year‑over‑year revenue growth, giving fundamental support for the analyst optimism and helping justify a higher valuation multiple. Read More.
• Neutral Sentiment: Priced upsized convertible notes ($475M of 0.50% convertible senior notes due 2032) to refinance 2029 convertibles — this improves near‑term liquidity and extends maturity but could be dilutive if converted; closing expected May 11. Read More.
• Neutral Sentiment: HC Wainwright trimmed some near‑ and mid‑term EPS forecasts (Q2/FY2026–FY2030 tweaks) but kept a Buy rating and $57 target — modest estimate changes that haven’t removed analyst support. Read More.
• Neutral Sentiment: Management will present at multiple investor conferences in May–June (BofA, Jefferies, Goldman Sachs), offering upcoming opportunities for fresh guidance or investor Q&A. Read More.
• Negative Sentiment: Heavy insider selling disclosed (CEO, directors and several executives sold shares, often under pre‑arranged Rule 10b5‑1 plans and to cover tax obligations); the scale of sales — including the CEO’s 22,500‑share sale — can create short‑term supply and investor concern despite plan disclosures. Read More. Read More.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in Travere Therapeutics during the second quarter valued at approximately $33,000. Fifth Third Bancorp acquired a new stake in shares of Travere Therapeutics in the first quarter worth $35,000. First Horizon Corp acquired a new stake in shares of Travere Therapeutics in the third quarter worth $36,000. State of Wyoming acquired a new stake in shares of Travere Therapeutics in the fourth quarter worth $37,000. Finally, Torren Management LLC acquired a new stake in shares of Travere Therapeutics in the fourth quarter worth $38,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.